Tradestie Institutional Equity Comparison Engine

OKYO vs STRO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

STRO Overall Edge

STRO Captures Institutional Edge (3โ€“1 Pillars ยท 5โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Sutro Biopharma, Inc. (STRO) driven by superior Valuation, Momentum & Technical, Options & Structure while OKYO counters with relative strength in Growth & Margin. Fundamentally, OKYO trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus STRO at 10.0x Forward P/E and -254.7% operating margin (-6.1% YoY). In options structure, OKYO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against STRO sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner STRO
OKYO N/M vs STRO 10.0x Fwd P/E
Growth & Margin Winner OKYO
Op Margin 0.0% vs -254.7% ยท YoY +0.0% vs -6.1%
Momentum & Technical Winner STRO
1Y -47.0% vs +845.0% ยท 52W Pos 3% vs 18%
Options & Structure Winner STRO
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (<1st %ile IV)
OKYO NASDAQ
OKYO Pharma Limited Ordinary Shares
Biological Products, (No Diagnostic Substances)
$1.07
-7.76% 1D
Market Cap $62.7M
1M Return -27.21%
1Y Return -47.03%
Forward P/E N/M
Unified AI Score
42.8 / 100 HOLD
Tech 38.0 Fund 54.0 Flow 50.0 Mom 45.0
STRO NASDAQ
Sutro Biopharma, Inc.
Biological Products, (No Diagnostic Substances)
$8.60
-1.38% 1D
Market Cap $144.8M
1M Return -16.42%
1Y Return +845.05%
Forward P/E 10.0x
Unified AI Score
44.1 / 100 HOLD
Tech 30.0 Fund 48.0 Flow 50.0 Mom 68.9

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: OKYO -47.03% STRO +845.05% Spread: +892.08 pp (STRO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
OKYO TTM Op. Margin: 0.0% STRO TTM Op. Margin: -254.7%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on OKYO vs STRO. Trailing 12-month operating profitability (OKYO 0.0% vs STRO -254.7%) and valuation multiples (OKYO N/M vs STRO 10.0x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: OKYO (3) vs STRO (5)
Institutional Metric OKYO STRO Criterion Row Winner
Market Capitalization Scale $62.7M $144.8M Larger Scale STRO
Trailing P/E Ratio Valuation N/M 10.0x Lower Multiple STRO
Forward P/E Ratio Valuation N/M 10.0x Lower Multiple STRO
Revenue Growth (YoY) Growth +0.0% -6.1% Higher Growth OKYO
Operating Margin (TTM) Profitability 0.0% -254.7% Higher Margin OKYO
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -263.8% -1810.0% Higher ROE OKYO
52-Week Range Position Momentum 3% ($1โ€“$3) 18% ($1โ€“$44) Stronger Trend STRO
Beta / 30D Volatility Risk Regime 1.00ฮฒ ยท 76% Vol 1.46ฮฒ ยท 76% Vol Lower Realized Risk Tie
Unified Institutional Score Composite Signal 42.8 / 100 (HOLD) 44.1 / 100 (HOLD) Higher Composite STRO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full OKYO vs STRO Buy Guide
OKYO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live OKYO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
STRO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live STRO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither OKYO nor STRO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.